Log in to save to my catalogue

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced he...

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced he...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e6438030eab2449d8f1c4414595c6e53

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

About this item

Full title

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Publisher

England: BioMed Central Ltd

Journal title

BMC gastroenterology, 2023-03, Vol.23 (1), p.101-101, Article 101

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is to clarify the reality of HPD in patients with advanced hepatocellular carcinoma (HCC) who were treated with atezolizumab...

Alternative Titles

Full title

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e6438030eab2449d8f1c4414595c6e53

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e6438030eab2449d8f1c4414595c6e53

Other Identifiers

ISSN

1471-230X

E-ISSN

1471-230X

DOI

10.1186/s12876-023-02731-5

How to access this item